CIPLA
LIVE

Serial Number

88171179

Owner

CIPLA LIMITED

Attorney

Stacey R. Halpern

Filing Date

Oct 26, 2018

Add to watchlist:

No watchlists yet
View on USPTO

CIPLA Trademark

Serial Number: 88171179 • Registration: 5894625

CIPLA is a trademark filed by CIPLA LIMITED on October 26, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

CIPLA LIMITED

Cipla House, Peninsula Business Park
Mumbai, Maharashtra 400013 , IN

Entity Type: 03

Trademark Details

Filing Date

October 26, 2018

Registration Date

October 29, 2019

Published for Opposition

August 13, 2019

Goods & Services

Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of gastro-intestinal disorders, disorders of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, seizures Huntington's disease, multiple sclerosis; Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of disorders of the respiratory system, heart conditions and other disorders of the cardiovascular system, namely, Coronary artery disease, Heart attack, abnormal heart rhythms, arrhythmias, heart failure, heart valve disease, congenital heart disease, cardiomyopathy, pericardial disease; Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of migraines and other forms of headache, namely, sinus headaches, tension headaches, cluster headaches and rebound headaches; pharmaceutical and medicinal preparations, namely, analgesics; pharmaceutical and medicinal preparations, namely, antiviral and anti-retroviral pharmaceutical preparations for the treatment of viral brain diseases; pharmaceutical and medicinal preparations, namely, anti-infectives; pharmaceutical and medicinal preparations, namely, anti-inflammatories; pharmaceutical and medicinal preparations, namely, antibiotics; pharmaceutical and medicinal preparations, namely, antidepressants; pharmaceutical and medicinal preparations, namely, anti-cancer preparations; pharmaceutical and medicinal preparations, namely, medicated soaps and lotions for the skin and hair, namely, medicated acne lotion, medicated body moisturizing lotion, medicated lotion for eczema and seborrheic dermatitis, medicated hair shampoo and hair scalp lotion, medicated anti-dandruff lotion; pharmaceutical and medicinal preparations, namely, decongestants and antihistamines; pharmaceutical and medicinal preparations, namely, scabicides; pharmaceutical and medicinal preparations, namely, anti-malarials; pharmaceutical and medicinal preparations, namely, cough suppressants; pharmaceutical and medicinal preparations, namely, cough and cold preparations; pharmaceutical and medicinal preparations, namely, expectorants; pharmaceutical and medicinal preparations, namely, anti-leukemic agents; pharmaceutical and medicinal preparations, namely, tissue sealants; pharmaceutical and medicinal preparations, namely, vasopressors; pharmaceutical and medicinal preparations, namely, nondepolarizing skeletal neuromuscular blocking agents; pharmaceutical and medicinal preparations, namely, preparations for the treatment of gout; pharmaceutical and medicinal preparations, namely, preparations for cessation of smoking; Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of genitourinary diseases and disorders, namely, urological diseases, urological disorders, urinary incontinence, infertility, sexually transmitted diseases, inflammatory pelvic diseases; Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of pain from burns, hemolytic diseases and disorders, neuropathic pain; Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of fibromyalgia, post-herpetic neuralgia, chronic pain, obesity, inflammation and inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, immunological diseases and disorders, namely, autoimmune diseases, immunologic deficiency syndromes, Acquired Immune Deficiency Syndrome (AIDS), viral diseases and disorders, namely, herpes, hepatitis, substance abuse disorders, namely, alcoholism and drug addiction, carpel tunnel syndrome, varicose veins, dental and oral diseases, osteoporosis, arthritis, yeast infections, prostate disorders, pulmonary disorders, sleep disorders, namely, insomnia and, restless leg syndrome, premature ejaculation, macular degeneration, thrombosis and thromboembolism; pharmaceutical and medicinal preparations, namely, vaccines for human use; pharmaceutical and medicinal preparations, namely, adjuvants for use with human vaccines; pharmaceutical and medicinal preparations in the nature of veterinary preparations, namely, flea and tick preparations, vaccines, anti inflammatories, mastitis preparations, and oncological preparations

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Apr 10, 2026 NAS8
REGISTERED - SEC. 8 (6-YR) ACCEPTED
Apr 10, 2026 8.OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 20, 2026 APRE
TEAS SECTION 8 RECEIVED
Oct 29, 2025 ES8R
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 29, 2024 REM1
REGISTERED-PRINCIPAL REGISTER
Oct 29, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 13, 2019 NPUB
PUBLISHED FOR OPPOSITION
Aug 13, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 24, 2019 NONP
ASSIGNED TO LIE
Jul 8, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 27, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 27, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 27, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 27, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 27, 2019 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 7, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 6, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 6, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 4, 2019 GNRN
NON-FINAL ACTION E-MAILED
Feb 4, 2019 GNRT
NON-FINAL ACTION WRITTEN
Feb 4, 2019 CNRT
ASSIGNED TO EXAMINER
Feb 4, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 9, 2018 NWOS
NEW APPLICATION ENTERED
Oct 30, 2018 NWAP